CA
NZ
UK
AU
IND
US
Serina Therapeutics (NYSE American: SER) said the U.S. Food and Drug Administration gave constructive feedback that supports advancing SER-252, a POZ-enabled apomorphine formulation aimed at treating advanced Parkinson’s disease, via a 505(b)(2) NDA pathway. The company plans to launch a registrational clinical development program …
Eisai Co., Ltd. and Biogen Inc. announced the first European launches of LEQEMBI® (lecanemab) in Austria on August 25, 2025, with Germany to follow on September 1, 2025 — the initial rollout following the European Commission’s marketing authorisation in April 2025. These are the …
argenx reported positive topline results from the Phase 3 ADAPT SERON study evaluating VYVGART® (efgartigimod) in patients with AChR-Ab seronegative generalized myasthenia gravis (gMG). The trial achieved its primary endpoint, with a reported p-value of 0.0068 for improvement on the Myasthenia Gravis Activities of …
Alvotech (NASDAQ: ALVO) and Advanz Pharma Holdco Limited said the European Commission has approved Mynzepli® as a biosimilar to Eylea® (aflibercept). The approval is a centralized marketing authorisation that covers all European Economic Area (EEA) countries — the 27 EU member states plus Norway, …
Smith & Nephew plc (NYSE: SNN) received a price target increase from Canaccord Genuity Group, moving to USD 36 from USD 28 while maintaining a Hold rating, according to a recent research note. The revision follows a period of reassessment across the sell-side: HSBC …
Alcon reported second-quarter 2025 results with net sales of approximately $2.6 billion, a 4% increase on a reported basis and 3% in constant currency versus the prior-year quarter. The company posted diluted earnings per share of $0.35 and core diluted EPS of $0.76 for …
ICU Medical (NASDAQ: ICUI) was upgraded tooverweightby Piper Sandler in a Friday report, with aUSD145price target that indicates an estimated17.92%upside from recent levels, according to MarketBeat. The change reflects a more favorable stance on the company’s near-term risk-reward and earnings trajectory within medical supplies …
Ascentage Pharma announced regulatory clearances from both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) to initiate GLORA-4, a global Phase III registrational study of lisaftoclax in combination with azacitidine for first-line treatment of higher-risk myelodysplastic syndrome (HR-MDS). The …
Evotec SE reported mixed first-half 2025 results, reflecting divergent trends across its businesses and a challenging discovery market. Group revenues declined 5% year over year to GBP371.2 million as Discovery & Preclinical Development (D&PD) revenue decreased 11% to GBP269.0 million, consistent with softer demand …
Shares of Cardinal Health, Inc. (NYSE: CAH) have received a consensus recommendation of “Moderate Buy” from fourteen research firms currently tracking the stock. Out of these, three analysts rate the stock as “Hold,” while eleven have issued “Buy” ratings.
Please wait processing your request...